Advertisement

Breast Cancer Research and Treatment

, Volume 130, Issue 1, pp 353–355 | Cite as

Re Panoff et al., Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation

  • Peter Graham
Letter to the Editor
  • 75 Downloads

To the Editor,

We were pleased to see Panoff et al.’s observations of excellent locoregional control [1]. Modern targeted systemic therapy for HER2 positive tumours seems to have made a positive impact with locoregional recurrence of only 1.7 and 6.2% in the overall population. We would, however, note that appropriate targeting of HER2 positive patients could only reduce expected recurrence in 23% of patients and this alone cannot explain the excellent results overall, since ER positive tumours have been routinely treated with anti-oestrogen therapy for decades. We note that over 90% of patients had a dose of 60 Gy to the chest wall which is higher than most adjuvant post-mastectomy trials. In addition, the higher dose of radiation halved local recurrence, which is consistent with the effect seen in breast conservation randomised trials of a boost dose of radiotherapy [2]. Since chest wall recurrence accounts for approximately 70% of locoregional recurrence and this intervention...

Keywords

Trastuzumab Systemic Therapy Locoregional Recurrence HER2 Positive Patient Triple Negative Phenotype 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Conflict of interest

None.

References

  1. 1.
    Panoff JE, Hrely J, Takita C, Reis IM, Zhao W, Sujoy V, Gomez CR, Jorda M, Koniaris I, Wright JL (2011) Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation. Breast Cancer Res Treat. doi: 10.1007/s10549-011-1495-1
  2. 2.
    Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, Jager JJ, Hoogenraad WJ, Oei SB, Warlam-Rodenhuis CC, Pierart M, Collette L (2007) Impact of a higher radiation dose on local control and survival in breast conserving therapy of early breast cancer: 10 year results of the randomized boost versus no boost trial of EORTC 22881–10882 Trial. J Clin Oncol 25:3259–3265PubMedCrossRefGoogle Scholar
  3. 3.
    Comen EA, Robson M (2010) Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer. Cancer J 16:48–52PubMedCrossRefGoogle Scholar
  4. 4.
    Efimova EV, Mauceri HJ, Golden DW, Labay E, Bindokas VP, Darga TE, Chakraborty C, Barreto-Andrade JC, Crawley C, Sutton HG, Kron SJ, Weichselbaum RR (2010) Poly(ADP-ribose) polymerase inhibitor induces accelerated senescence in irradiated breast cancer cells and tumors. Cancer Res 70:6277–6282PubMedCrossRefGoogle Scholar
  5. 5.
    Liu SK, Coackley C, Krause M, Jalali F, Chan N, Bristow RG (2008) A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. Radiother Oncol 88(2):258–268PubMedCrossRefGoogle Scholar
  6. 6.
    Taghian A, Jeong J-H, Mamounas E, Anderson S, Bryant J, Deutsch M, Wolmark N (2004) Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol 22(21):4247–4254PubMedCrossRefGoogle Scholar

References for Rebuttal letter

  1. 1.
    Panoff JE, Takita C, Hurley J et al (2011) Higher chest wall dose results in improved locoregional outcome in patients receiving postmastectomy radiation. Int J Radiat Oncol Biol Phys [Epub ahead of print]Google Scholar

Copyright information

© Springer Science+Business Media, LLC. 2011

Authors and Affiliations

  1. 1.Cancer Care CentreSt George HospitalKogarahAustralia

Personalised recommendations